Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
51 hedge funds and large institutions have $287M invested in Tourmaline Bio in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 51 → 51 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
0.17% less ownership
Funds ownership: 7.22% → 7.05% (-0.17%)
37% less capital invested
Capital invested by funds: $457M → $287M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$706K |
| 2 |
BlackRock
New York
|
+$360K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$234K |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$211K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.96M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$4.17M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$590K |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$299K |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$213K |
TRML Hedge Fund Activity: Q1 2022 in Review
51 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q1 2022, worth a combined $287M — down 37% from $457M a quarter earlier.
Fund positioning in TRML was balanced in Q1 2022: 7 funds opened new positions, 7 closed out, 14 added to existing stakes and 14 trimmed.
The largest buyer was State Street, adding an estimated $706K. The largest seller was Avidity Partners Management, exiting entirely with an estimated $6.96M sold.
- 51 institutional investors held Tourmaline Bio (TRML) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $287M of Tourmaline Bio stock for Q1 2022, down 37% quarter-over-quarter.
- 7 funds opened new Tourmaline Bio positions in Q1 2022 and 7 closed out, a net change of 0 holders.
- The largest Tourmaline Bio buyer in Q1 2022 was State Street, an estimated $706K added.
- The largest Tourmaline Bio seller in Q1 2022 was Avidity Partners Management, an estimated $6.96M sold.
Based on aggregated 13F filings for Q1 2022.